SCREENING PARADIGM FOR ?-THALASSEMIA CARRIERS; FROM CLINICAL TO MOLECULAR

? thalassemia (?-thal) represents a major health problem worldwide and particularly in Egypt. Its prevention, when compared to treatment, is found to be cost-effective, possible and practical. This work aimed to evaluate the effectiveness of diagnostic techniques in detection of the ?-thalassemia c...

Full description

Bibliographic Details
Main Authors: Ibrahim Youssef, soha youssef, Galila Mokhtar, Mahira I. Elmogy, Hanan M. Mahmoud, maryse soliman ayoub, Shaimaa A. Pessar
Format: Article
Language:English
Published: PAGEPress Publications 2014-08-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Online Access:https://mjhid.org/index.php/mjhid/article/view/1736
id doaj-dfd109365dbd44a1958c3f30cf814446
record_format Article
spelling doaj-dfd109365dbd44a1958c3f30cf8144462020-11-25T03:26:08ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062014-08-011SCREENING PARADIGM FOR ?-THALASSEMIA CARRIERS; FROM CLINICAL TO MOLECULARIbrahim Youssef0soha youssef1Galila Mokhtar2Mahira I. Elmogy3Hanan M. Mahmoud4maryse soliman ayoub5Shaimaa A. Pessar6Ain Shams UniversityProfessor of clinical pathology Ain shams universityAin-Shams universityAin shams universityAin shams universityass.profAin shams university ? thalassemia (?-thal) represents a major health problem worldwide and particularly in Egypt. Its prevention, when compared to treatment, is found to be cost-effective, possible and practical. This work aimed to evaluate the effectiveness of diagnostic techniques in detection of the ?-thalassemia carrier state. The present work included 1627 child and adolescent of both sexes presenting as outpatients to clinics of Ain-Shams University Hospitals during period from 1/11/2009 to 30/6/2010. In the first phase microcytic hypochromic for age CBCs were selected. In the second phase, Iron profile and HPLC testing were performed. Molecular characterization by PCR reverse hybridization for detection of 22 common ?-globin gene mutations was done as a final step. The 280 Microcytic hypochromic cases selected were further analyzed by iron profile & HPLC. This revealed 100 suspected cases in whom a Hb A2 >4% was able to identify ? thalassemia carriers with 97.4% sensitivity, 72.7% specificity and 92% diagnostic accuracy while a HbA2 borderline value from 3.6% to 4% provided 100% sensitivity & 70% diagnostic accuracy. Further genotyping of the latter group confirmed presence of Beta thalassemia related mutations in 74% of the suspected cases. Conclusion: In addition to HPLC, as a reliable primary screening tool for ?-thalassemia trait (?TT), molecular testing is mandatory for selected cases with borderline Hb A2 values. https://mjhid.org/index.php/mjhid/article/view/1736anemiathalassemia
collection DOAJ
language English
format Article
sources DOAJ
author Ibrahim Youssef
soha youssef
Galila Mokhtar
Mahira I. Elmogy
Hanan M. Mahmoud
maryse soliman ayoub
Shaimaa A. Pessar
spellingShingle Ibrahim Youssef
soha youssef
Galila Mokhtar
Mahira I. Elmogy
Hanan M. Mahmoud
maryse soliman ayoub
Shaimaa A. Pessar
SCREENING PARADIGM FOR ?-THALASSEMIA CARRIERS; FROM CLINICAL TO MOLECULAR
Mediterranean Journal of Hematology and Infectious Diseases
anemia
thalassemia
author_facet Ibrahim Youssef
soha youssef
Galila Mokhtar
Mahira I. Elmogy
Hanan M. Mahmoud
maryse soliman ayoub
Shaimaa A. Pessar
author_sort Ibrahim Youssef
title SCREENING PARADIGM FOR ?-THALASSEMIA CARRIERS; FROM CLINICAL TO MOLECULAR
title_short SCREENING PARADIGM FOR ?-THALASSEMIA CARRIERS; FROM CLINICAL TO MOLECULAR
title_full SCREENING PARADIGM FOR ?-THALASSEMIA CARRIERS; FROM CLINICAL TO MOLECULAR
title_fullStr SCREENING PARADIGM FOR ?-THALASSEMIA CARRIERS; FROM CLINICAL TO MOLECULAR
title_full_unstemmed SCREENING PARADIGM FOR ?-THALASSEMIA CARRIERS; FROM CLINICAL TO MOLECULAR
title_sort screening paradigm for ?-thalassemia carriers; from clinical to molecular
publisher PAGEPress Publications
series Mediterranean Journal of Hematology and Infectious Diseases
issn 2035-3006
publishDate 2014-08-01
description ? thalassemia (?-thal) represents a major health problem worldwide and particularly in Egypt. Its prevention, when compared to treatment, is found to be cost-effective, possible and practical. This work aimed to evaluate the effectiveness of diagnostic techniques in detection of the ?-thalassemia carrier state. The present work included 1627 child and adolescent of both sexes presenting as outpatients to clinics of Ain-Shams University Hospitals during period from 1/11/2009 to 30/6/2010. In the first phase microcytic hypochromic for age CBCs were selected. In the second phase, Iron profile and HPLC testing were performed. Molecular characterization by PCR reverse hybridization for detection of 22 common ?-globin gene mutations was done as a final step. The 280 Microcytic hypochromic cases selected were further analyzed by iron profile & HPLC. This revealed 100 suspected cases in whom a Hb A2 >4% was able to identify ? thalassemia carriers with 97.4% sensitivity, 72.7% specificity and 92% diagnostic accuracy while a HbA2 borderline value from 3.6% to 4% provided 100% sensitivity & 70% diagnostic accuracy. Further genotyping of the latter group confirmed presence of Beta thalassemia related mutations in 74% of the suspected cases. Conclusion: In addition to HPLC, as a reliable primary screening tool for ?-thalassemia trait (?TT), molecular testing is mandatory for selected cases with borderline Hb A2 values.
topic anemia
thalassemia
url https://mjhid.org/index.php/mjhid/article/view/1736
work_keys_str_mv AT ibrahimyoussef screeningparadigmforthalassemiacarriersfromclinicaltomolecular
AT sohayoussef screeningparadigmforthalassemiacarriersfromclinicaltomolecular
AT galilamokhtar screeningparadigmforthalassemiacarriersfromclinicaltomolecular
AT mahiraielmogy screeningparadigmforthalassemiacarriersfromclinicaltomolecular
AT hananmmahmoud screeningparadigmforthalassemiacarriersfromclinicaltomolecular
AT marysesolimanayoub screeningparadigmforthalassemiacarriersfromclinicaltomolecular
AT shaimaaapessar screeningparadigmforthalassemiacarriersfromclinicaltomolecular
_version_ 1724593943960616960